Medical School：Institut Pasteur of Shanghai, Chinese Academy of Sciences, China
Academic Rank：Associate Professor
Harold C. and Mary L. Daily Endowment Postdoctoral Fellowships, 2016
Outstanding Research Publication Award, the Ernst W. Bertner Memorial Fund, MD Anderson Cancer Center, 2016
Best Poster Award, 14th International Workshop KSHV, 2011
Academic Achievement Scholarship, Chinese Academy of Sciences, 2006 - 2011
Di'Ao Scholarship, Chinese Academy of Sciences, 2008
Member, Chinese Society of Microbiology, 2007–2011
Member, Metastasis Research Society, 2012–present
Member, American Association for Cancer Research (AACR), 2012–present
Reviewer for Chin. J. Cancer Res., Virology, PLOS ONE, Cancer, 2013–present
Over the last decade, cancer immunotherapy, especially checkpoint inhibitors, has revolutionized the clinical management of multiple difficult-to-treat tumor types. However, there only less than 30% of patient will have durable clinical responses. There is now an urgent need to identify mechanisms of immunotherapy resistance, to predict outcome and to identify targets for combination therapy, which is at the forefront of current basic and translational cancer research.
An intense focus of research in lab of Dr. Liu is to investigate the molecular and cellular mechanisms underlying the cancer development, metastasis and immune evasion. They are also interested in identifying biomarkers and context-specific therapeutic targets for personalized cancer medicine. Their mission is to eliminate cancer as a chronic disease in the near future through bench-to-bedside translational research and pharmaceutical partnerships.
Xu J*, Liu Y*, Wang H, Stewart S, Agarwal P, Zhang Y, Liu S, Wan J, Lu X, He X. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat. Nanotechnol. 2019 Apr;14(4):388-397. (* co-first author)
Liu Y, Xu J, Li Y, Lu X, He X, Zhang X. The 17q23 amplification promotes mammary tumorigenesis and contributes to the resistance of anti-HER2 therapy. Nat Commun. 2018;9(1):4718.
Li Y*, Liu Y*, Xu H*, Li Z, Deng Sizovs A, Zhang X, D, Logsdon C, Wang J, Lu X. Heterozygous Deletion of Chromosome 17p Renders Castration-resistant Prostate Cancer Vulnerable to the Inhibition of RNA Polymerase II. Nat Commun. 2018;9(1):4394. (* co-first author)
Liu Y#, Xu H, Van der Jeught K, Li Y, Ji G, Lu X#. Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in human cancer. J Clin Invest. 2018 128(7):2951-2965. (# corresponding author)
Han C, Yang L, Choi H, Baddour J, Achreja A, Liu Y, Li Y, Nagrath D, Lu X. Amplification of USP13 Drives Ovarian Tumor Metabolism. Nature Communications. 2016;7:13525.
Liu Y, Li Y, Lu X. Regulators in the DNA damage response. Archives of Biochemistry and Biophysics. 2016;594:18-25.
Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2015;520(7549):697-701.
Liu Y, Wang L, Lu X. A new way to target p53-defective colorectal cancer. Future Oncology. 2015;11(23):3101-4.
Liu Y, Hu X, Han C, Wang L, Zhang X, He X, Lu X. Targeting tumor suppressor genes for cancer therapy. BioEssays. 2015;37(12):1277-86.
Wan G, Liu Y, Han C, Zhang X, Lu X. Noncoding RNAs in DNA repair and genome integrity. Antioxidants & redox signaling. 2014;20(4):655-77.
Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan C, He X, Sood AK, Zhang X, Lu X. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell reports. 2014;8(5):1447-60.